Despite reports of the strong killing function of NK cells more than four decades ago, adoptive therapy strategies to exploit this property against late-stage cancer cells have had limited success in the clinic. A major obstacle to translation has been the lack of reliable methods to enhance the inadequate persistence and reduced activity of NK cells after their infusion into patients. Thus, the long-term goal of Project 3 is to devise novel adoptive cell-based therapies for advanced B-lymphoid malignancies (such as acute lymphoblastic leukemia, chronic lymphocytic leukemia and non-Hodgkin lymphoma). The central hypothesis is: (i) the killing function of cord blood (CB)-derived NK cells against hematologic cancers can be substantially enhanced with minimal adverse toxicity, including graft-vs.-host disease, by genetically modifying the cells to express a CD19- specific chimeric antigen receptor (CAR), a suicide gene (inducible caspase-9, or iC9) and the IL-15 cytokine to support NK cell proliferation and durability; and ( ii ) it may be feasible to boost this activity by inhibiting the CISH gene, thus abolishing a pivotal cytokine signaling checkpoint in NK cells and making it possible to consider the use of lower doses of cell therapy without loss of efficacy. This combined strategy, based on our recent preliminary findings as well as the transformative successes with CAR.CD19-redirected T cells, will be pursued in three specific aims.
In Aim 1, a first-in-human phase I/II clinical trial, we will evaluate the safety and antitumor activity iC9/CAR.19/IL15-transduced CB-NK cells in 36 patients with advanced leukemia or lymphoma.
Aim 2 seeks to track the in vivo fate of the transduced cells described above and correlate the findings with disease responses recorded in Aim 1. This approach will enable us to address several fundamental issues that have been persistent barriers to more effective modes of adoptive NK cell therapy for patients with cancer. Finally, Aim 3 will target CIS, a cytokine signaling checkpoint in NK cells, to further improve the therapeutic potential of our strategy. If we succeed in avoiding toxicity (cytokine release syndrome, for example) that may be associated with targeted therapies of this type, our project will mark a clear advance in the development of novel cellular treatments for cancer.
In this proposal, we seek to improve the outcome of patients with advanced B-lymphoid cancers by harnessing the power of natural killer (NK) cells, which are manufactured in our laboratory from cord blood and modified to recognize a common molecule, CD19, on B cell leukemia and lymphoma. The safety and effectiveness of this strategy will be tested in a clinical trial in patients whose cancers are resistant to conventional treatment. We will also be testing methods to make our genetically-modified NK cells more effective at lower doses by targeting the intracellular checkpoint molecule, CIS, potentially overcoming the need to infuse higher doses of CAR NK cells with their associated toxicity. 1
|Agha, Nadia H; Baker, Forrest L; Kunz, Hawley E et al. (2018) Vigorous exercise mobilizes CD34+ hematopoietic stem cells to peripheral blood via the ?2-adrenergic receptor. Brain Behav Immun 68:66-75|
|Yang, Tian-Hui; St John, Lisa S; Garber, Haven R et al. (2018) Membrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation. J Immunol 201:1389-1399|
|Barrett, A John; Prockop, Susan; Bollard, Catherine M (2018) Virus-Specific T Cells: Broadening Applicability. Biol Blood Marrow Transplant 24:13-18|
|Trujillo-Ocampo, Abel; Cho, Hyun-Woo; Herrmann, Amanda C et al. (2018) Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease. Cytotherapy 20:1089-1101|
|Simpson, Richard J; Bigley, Austin B; Agha, Nadia et al. (2017) Mobilizing Immune Cells With Exercise for Cancer Immunotherapy. Exerc Sport Sci Rev 45:163-172|
|Kerros, Celine; Tripathi, Satyendra C; Zha, Dongxing et al. (2017) Neuropilin-1 mediates neutrophil elastase uptake and cross-presentation in breast cancer cells. J Biol Chem 292:10295-10305|
|Cruz, Conrad R Y; Bollard, Catherine M (2017) Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells. Curr Drug Targets 18:271-280|
|Robinson, Simon N; Thomas, Michael W; Simmons, Paul J et al. (2017) Non-fucosylated CB CD34+ cells represent a good target for enforced fucosylation to improve engraftment following cord blood transplantation. Cytotherapy 19:285-292|
|Houghtelin, Amy; Bollard, Catherine M (2017) Virus-Specific T Cells for the Immunocompromised Patient. Front Immunol 8:1272|
|Peters, Haley L; Tripathi, Satyendra C; Kerros, Celine et al. (2017) Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. Cancer Immunol Res 5:319-329|
Showing the most recent 10 out of 102 publications